AstraZenecaAZN
MetabolicOncology80 cited findings · profile updated 2026-08-24
165.98 USDnot live — refreshed daily
About AstraZeneca
AstraZeneca (AZN) focuses on metabolic and oncology therapeutic areas. In oncology, the company's drug Lynparza has been studied across multiple trials. For instance, in the SOLO-2 trial, nausea (grades 1-4) was observed in 76% of patients in the Lynparza arm, compared to 33% in the placebo arm. Anemia (grades 3-4) was reported in 20% of the Lynparza arm versus 2% in the placebo arm in the same trial. In the PAOLA-1 trial, Lynparza/bevacizumab arm showed 17% anemia (grades 3-4) compared to 0.4% in the placebo/bevacizumab arm.
In the metabolic area, AstraZeneca has received European Union approval for dapagliflozin (FORXIGA) in November 2012. EBYMECT FDC also received EU approval on 16 November 2015. The DECLARE trial, a Phase IIIb study, investigated dapagliflozin at a 10 mg dose, with an assumed HR for MACE superiority of 0.85 and 85% power to demonstrate MACE superiority. Minor hypoglycaemia rates with placebo + insulin at Week 104 were 41.6%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Nausea (grades 1-4) in Lynparza arm | 76 % | AstraZeneca PLC — Lynparza FDA Review (NDA/BLA 208558, 2025), p.23 |
| Nausea (grades 1-4) in placebo arm | 33 % | AstraZeneca PLC — Lynparza FDA Review (NDA/BLA 208558, 2025), p.23 |
| Anemia (grades 3-4) in Lynparza arm | 20 % | AstraZeneca PLC — Lynparza FDA Review (NDA/BLA 208558, 2025), p.23 |
| Anemia (grades 3-4) in placebo arm | 2 % | AstraZeneca PLC — Lynparza FDA Review (NDA/BLA 208558, 2025), p.23 |
| Dapagliflozin EU approval date (FORXIGA) | November 2012 | AstraZeneca PLC — Ebymect EMA EPAR variation assessment report (EMEA/H, p.7 |
| EBYMECT FDC EU approval date | 16 November 2015 | AstraZeneca PLC — Ebymect EMA EPAR variation assessment report (EMEA/H, p.7 |
Key projects
- Lynparza (oncology)
Nausea (grades 1-4) in Lynparza arm was 76% in the SOLO-2 trial, compared to 33% in the placebo arm.
- Lynparza/bevacizumab (oncology)
Decrease in hemoglobin (grades 3-4) was 13% in the Lynparza/bevacizumab arm in PAOLA-1, compared to 0.4% in the placebo/bevacizumab arm.
- FORXIGA (metabolic) — European Union
Dapagliflozin EU approval date (FORXIGA) was November 2012.
- Ebymect (metabolic) — European Union
EBYMECT FDC EU approval date was 16 November 2015.
- DECLARE (metabolic)
The DECLARE trial, a Phase IIIb study, had an assumed HR for MACE superiority of 0.85.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Metabolic research library →